RESEARCH

Incidence of anemia and predictors among Human Immunodeficiency Virus-infected children on antiretroviral therapy at public health facilities of Bahir Dar City, Northwest Ethiopia: multicenter retrospective follow up study

Gashaw Kerebeh1*, Yeneneh Ayalew2, Demewoz Kefale1, Ermias Sisay Chanie1, Natnael Moges Misganaw1, Dejen Getaneh Feleke1, Amare Kassaw1, Agimasie Tigabu3, Berihun Bantie3, Mahlet Tamirat2, Teshale Mengesha4, Molla Azmeraw5 and Aklilu Endalamaw2,6

Abstract

Background: Anemia is one of the common hematological problems among HIV-infected children. It impairs physical functioning, affects the quality of life, increases HIV progression, and decreases survival of HIV-infected children. In Ethiopia, limited studies were conducted on the incidence and predictors of anemia among HIV-infected children on antiretroviral therapy (ART). Therefore, this study aims to assess the incidence of anemia and predictors among HIV-infected children on ART at public health facilities of Bahir Dar City, Northwest Ethiopia.

Methods: An institution-based retrospective follow-up study was conducted among 403 HIV-infected children who have followed at ART clinics in public health facilities of Bahir Dar City from 2010 to 2020. A simple random sampling technique was employed to select the study units. Data was entered using Epi-data version 4.6 and analyzed using STATA 14.0. Cox proportional hazard model assumption was checked graphically and by scaled Schoenfeld residual test. Bivariable Cox-proportional hazards regression model was employed for each explanatory variable to check the association with the outcome variable. Variables with a p-value of < 0.2 in the bivariable analysis were candidates to the multivariable proportional hazard model. Cox proportional hazards model was used at a 5% level of significance to identify predictors of anemia.

Results: The overall follow up time was 1587 person–years. The overall incidence density of anemia was 6.87 with 95% confidence interval (CI) = (5.60, 8.16) per 100 person-years. The independent predictors show an association were child age from 0.25 to 5 years adjusted hazard ratio (AHR) = (1.83; 95% CI = 1.22, 2.77), World health organization clinical stage III and IV (AHR = 1.80; 95% CI = 1.22, 2.67), being underweight (AHR = 1.5; 95% CI = 1.01, 2.26), having

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

*Correspondence: gashawkerebeh22@gmail.com
1 Department of Pediatrics and Child Health Nursing, College of Health Sciences, Debre Tabor University, P.O. Box: 272, Debre Tabor, Ethiopia
Full list of author information is available at the end of the article
Background

Hematological abnormalities are common problems in children diagnosed with Human Immunodeficiency Virus [1–3]. Anemia is the most common hematological manifestation in children who are on antiretroviral therapy (ART) [2, 4], which has a significant impact on the quality of life and clinical outcomes unless treated appropriately [5]. Moreover, anemia has serious effects, varying from a physical functioning impairment, psychological distress, and affects the quality of life to an association with disease progression and decreased survival, leading to death [6]. Besides the direct effect of HIV by itself, highly active antiretroviral therapy (HAART) also becomes a cause for anemia like that of Zidovudine (AZT) is known to cause bone marrow suppression [7, 8]. It is a major public health problem affecting an estimated 2 billion people worldwide, with more than 100 million of these anemic children living in Africa [7]. In Africa, the prevalence of anemia after initiation of ART in the pediatrics age group was 54.2% [5]. In Ethiopia, the overall prevalence of anemia among HIV- infected children ranged from 22.3–57.5% [9, 10]. This report also showed that the trend of anemia prevalence among Ethiopian children decreased from 54 to 44% from 2005 to 2011 but increased to 57% in 2016 [10]. Moreover, the incidence of anemia among HIV- infected children was reported in different countries. As reported in Asia, the incidence density rate of severe anemia among children after antiretroviral therapy (ART) initiation was 5.4 per 100 person-years [11]. Similarly, in West Africa, it was 2.47–4.25 per 100 person-year [8]. And in the previous study of Ethiopia, that reports 10.5 per 100 person-years of observation [12].

To prevent and control the incidence of anemia among HIV- infected children, there are different tried solutions at the national and international level. Notably, measuring of serum hemoglobin level before starting ART [13], starting with non-zidovudine (AZT) based ART regimen [14], early initiation of ART [15]. Additionally, start cotrimoxazole prophylaxis for eligible children [16], maintain appropriate nutritional status [17], early diagnosis and management of opportunistic infections (OI) [18], close monitoring of CD4 count and viral load copies [19] has been used as a multi-dimensional approach.

Despite these approaches, there are identified predictors in the previous studies which increases the incidence of anemia like undernutrition [17], low CD4 count [20], taking AZT based ART drug regimen [21], being rural residency [22], advanced disease stage and OI [23].

Even though post ART anemia increases in children, studies on incidents and predictors of anemia among children initiating ART were limited; most studies were conducted on the prevalence of post ART anemia in different areas of the World. Similarly, in our country Ethiopia, data on incidents of anemia and predictors among children who are on ART is limited. Therefore, this study aims to assess the incidence of anemia and predictors among HIV- infected children at public health facilities of Bahir Dar City, Northwest Ethiopia.

The results found from this study provide valuable information for policymakers, clinicians, and researchers to enhance decision-making and planning of appropriate interventional strategies to reduce the incidence of anemia in HIV-infected children.

Methods and materials

Study design, setting, and period

An Institution-based retrospective follow-up study was conducted at public health facilities of Bahir Dar City, Northwest Ethiopia. Bahir Dar City has located 565 km from Addis Ababa, the capital City of Ethiopia. According to the 2020Bahir Dar City administration Health Department report, the total population is 389,177. Of these, 147,983 were children less than 15 years. The City has three governmental Hospitals (one specialized teaching Hospital, one comprehensive specialized referral Hospital, one primary Hospital) and ten governmental health centers. From the governmental health facilities, two Hospitals and eight Heath centers provide ART services for HIV- infected children. In the above health facilities, there are a total of 1,117 HIV- infected children who started ART since ART service started, and there are a total of 763 live HIV- infected children on ART follow up till now. Data were extracted from those children who...
started ART follow-ups between September 1, 2010, and December 31, 2020.

**Source population**
All HIV infected children < 15 years of age started ART at public health facilities of Bahir Dar City ART clinic.

**Study population**
All HIV-infected children < 15 years of age started ART at public health facilities of Bahir Dar City ART clinic from September 1, 2010, to December 30, 2020.

**Eligibility criteria**

**Inclusion criteria**
All HIV-infected Children < 15 years of age who took ART at least one month within September 1, 2010, to December 30, 2020.

**Exclusion criteria**
Children who had anemia at baseline and transferred from other health facilities were excluded from the study. Additionally, children with incomplete chart recording at baseline and during the follow-up period, especially important variables like age, sex, serum HGB level, weight, height, ART regimen, date of ART initiation, and date event or censored reported excluded from the study.

**Sample size determination and sampling procedure**
The sample size was determined using Log-rank test through open STATA version 14.0 statistical software with the assumptions of 95% CI, exposed to unexposed ratio 1:1, the margin of error 5%, power 80%, and 10% for incomplete chart records, which was calculated by taking significantly associated predictor for the incidence of anemia (being male sex) 4.6% and adjusted hazard ratio (AHR:2.36), from studies conducted on incidence and predictors of severe anemia in Asian HIV-infected children [11]. First, all public health facilities providing ART services in Bahir Dar City are identified. Then, the lists of children who have started ART during the study period were obtained from their registration book and electronic database in each health facility. Next, the sampling frame was constructed by adding from each health facility among medical records of children on ART. Finally, from the constructed sampling frame, HIV-infected children were selected randomly by using a computer-generated simple random sampling technique.

The total sample size of 422 HIV-infected children were selected from the health facilities (Fig. 1).

**Study Variables**
The dependent variable was the incidence of anemia. The independent variables include socio-demographic variables of the child (age, sex, residence, family size, parental live status). The socio-demographic variables of caregiver were age, HIV status, occupation, educational status, relation with the child, marital status. Clinical, laboratory and treatment-related characteristics (WHO clinical stage, CD4 count, Serum Hemoglobin level, Nutritional status, past TB history, initial ART regimen, time of ART initiation, regimen change, treatment duration, level of adherence, OI prophylaxis, current TB treatment, medication side effect, and viral load copies).

**Operational definitions**

**Event:** the occurrence of anemia during the follow-up time.

**Anemia:** anemia is defined as a hemoglobin level less than 11 g/dl for children < 5 years old, < 11.5 g/dl for children 5–11.9 years old, and < 12 g/dl for children 12–14.9 years [24].

**Time-to-event:** Defined as the time interval between the date when follow-up started and the occurrence of anemia.

**Censored:** when HIV-infected children withdraw, lost, transfer out, dead or the study period ends before HIV-infected children develop anemia.

**ART initiation:** it can be explained as early initiation or late initiation. Early initiation: defined as ART initiation within seven days of HIV diagnosis provided no contraindications. Late initiation: defined as ART initiation after seven days of HIV diagnosis.

**Nutritional status:** classified as Well-nourished, mild malnourished, moderately malnourished, and severely malnourished [25].

**Well nourished:** according to WHO growth curve weight/age < 1 & ≥ -1 z score, height/age < 1 & ≥ -1 z score, weight/height < 1 & ≥ -1 z score.

**Mild under nutrition:** according to WHO growth curve weight/age < -1, ≥ -2 z score, height/age < -1, ≥ -2 z score, weight/height < -1, ≥ -2 z score.

**Moderate under nutrition:** according to WHO growth curve weight/age < -2, ≥ -3 z score, height/age < -2, ≥ -3 z score, weight/height < -2, ≥ -3 z score.

**Severe under nutrition:** according to WHO growth curve weight/age < -3 z score, height/age < -3 z score, weight/height < -3 z score.

**Past TB history:** a child who had TB and completed the anti-TB treatment before enrolment in this study.

**ART Adherence:** is defined as "good" if the child took ≥ 95% (missing one from 30 doses or three out of 60 doses), "fair" if the child took 85–94% (missing 2–4 doses out of 30 doses or 4–9 from 60 doses or "poor" if the child took < 85% (missing ≥ 5 doses from 30 doses or > 10 from 60 doses during follow up [26].
Fig. 1  Sampling procedure for incidence and predictors of anemia among HIV- infected children on ART at public health facilities of Bahir Dar City, Northwest Ethiopia, from 2010 to 2020

**Key:**
- N = number of HIV-infected children on ART in each public health facility
- Fh – Felege Hiwot comprehensive Specialized Hospital
- Ad – Addisalem Primary Hospital
- She – Shembete health center
- Shu – Shamabo health center
- Ba – Bahir Dar health center
- Dm – Dagimawi Minilik II health center
- Ti – Tis abay health center
- Ha – Han health center
- Ab – Abay health center
- Zen – Zenzelima health center

The total number of children who started ART during the study period (TN = 779)

Simple random sampling technique

422
Data collection tool and procedure
Data were collected from HIV-infected children charts using a prepared and pre-tested data extraction structured checklist, adapted from WHO ART follow-up forms and intake form [27] included by reviewing related literature. Data were collected regarding HIV-infected children's socio-demographic variables, clinical, laboratory, and treatment-related variables. Three bachelors of science (BSc) nurses who have experience working in ART clinics and took comprehensive ART training were selected for data collection. One BSc nurse who has a comprehensive ART training certificate was selected for supervisor. The charts were retrieved using medical registration numbers from the computer database.

Data quality assurance
A pre-test was conducted at Bahir Dar Health center among 22 medical records of children on ART using the prepared checklist before 02 weeks of the actual data collection period to check the consistency of the checklist and availability of study variables. Two days of training were provided for data collectors, how to review the documents and extract data from medical records. And for one supervisor, how to supervise the entire data collection process. The filled formats were checked for completeness by the data collectors, supervisor, and principal investigator each day, and data cleaning was done during data collection and analysis time. Once data were extracted from patient charts, it was coded to avoid duplication.

Data processing and analysis
The collected data were coded and entered into EPI data version 4.6, and it was exported into STATA version 14.0 for cleaning and analysis. WHO anthro and WHO anthroplus software was used to calculate the Z-score of weight for age, body mass index for age, height for age, and height for weight to determine the nutritional status of children. Descriptive and summary statistics were computed to determine frequencies and proportions. Multicollinearity was checked using correlation coefficient (the value was less than 0.6) and variance inflation factor (the average VIF was 1.45).

Cox proportional hazard model assumption was checked graphically with the log–log plot of survival estimate and by scaled Schoenfeld residual test (p-value greater than 0.05 was met the assumption). The overall model fitness was checked using the cox–Snell residual test. The incidence rate of anemia was calculated using person-years of observation as a denominator for the entire study period. Kaplan Meier survival curve was used to estimate the anemia-free probability time and survival function estimation among different groups of categorical explanatory variables to compare with the support of log-rank test.

The bivariate Cox-proportional hazards regression model was employed for each explanatory variable to check the association with the outcome variable. Variables with a p-value of <0.2 in the bivariate analysis were candidates to the multivariable proportional hazard model. A 95% CI of hazard ratio (HR) was computed, and variables with a p-value less than 0.05 in the multivariable model were considered significantly associated with the dependent variable. Missing values were identified in four variables, and the percentage was ranged from 1.2% to 3.5% so, multiple imputations were implemented to fill the missed values.

Ethical considerations
Ethical clearance was obtained from the Ethical Review Board of Bahir Dar University College of Medicine and Health Sciences with IRB number (CMHS/IRB 01–008). A supporting letter was obtained from each selected health facility general manager, health center head, and coordinator. Information in the data extraction tool was anonymous. Files of entered data in the software and the final result of the study were protected with a password. The confidentiality of information was kept throughout the entire study process, and the information was used only for the study purpose.

Results
Baseline Socio-demographic characteristics of children on ART
A total of 422 charts were reviewed. Of which, 403 medical records of HIV-infected children on ART were included in the analysis that provided a completeness rate of 95.5%. The median age of HIV-infected children during ART initiation was eight years with IQR [5, 10]. More than half (53.35%) of the participants were males. The majority (82.13%) of children were from an urban area, and two-thirds (66.50%) of the children had a family size of less than three (Table 1).

Baseline socio-demographic characteristics of caregiver and parents
More than half (62.03%) of the HIV-infected children's parents, both mother, and father, were alive, And almost more than two-thirds (90.07%) of the HIV-infected children were living with their parents. Nearly greater than half (62.03%) of parents were married. More than one-third (44.67%) of HIV-infected children, parents both father and mother were HIV positive (Table 2).
Regarding opportunistic infections at baseline, (53.85%) of HIV-infected children were experienced opportunistic infections. Of which, (19.8%) had recurrent upper respiratory tract infections followed by herpes zoster (14.7%), tuberculosis (14.7%), and bacterial pneumonia (13.8%). More than two-thirds (84.37%) of HIV-infected children took cotrimoxazole prophylaxis during ART initiation. Related to the initial ART regimen started for the participants, 37.46% of children initiated with a combination of AZT-3TC-NVP. Of the total HIV-infected children, about 45.66% of children were stunted, and 42.18% of participants were underweight (Table 3).

### Table 1: Anemia incidence density rate stratified by baseline Socio-demographic characteristics of children on ART at public health facilities of Bahir Dar City, Northwest Ethiopia from 2010 to 2020

| Variable          | N = 403 (%) | Anemia N = 109 | Censored N = 294 | Person-Years | IDR/100 PYO |
|-------------------|-------------|----------------|-------------------|--------------|-------------|
| Sex               |             |                |                   |              |             |
| Male              | 215 (53.35) | 60             | 155               | 850.56       | 7.05        |
| Female            | 188 (46.65) | 49             | 139               | 737.19       | 6.64        |
| Age of child      |             |                |                   |              |             |
| 0.25—\leq 5      | 120 (29.78) | 42             | 78                | 428.87       | 9.79        |
| 6–10              | 186 (46.15) | 43             | 143               | 788          | 5.46        |
| 11–14             | 97 (24.07)  | 24             | 73                | 370.88       | 6.47        |
| Residence         |             |                |                   |              |             |
| Urban             | 331 (82.13) | 93             | 238               | 1300.48      | 7.15        |
| Rural             | 72 (17.87)  | 16             | 56                | 287.26       | 5.57        |
| Family size       |             |                |                   |              |             |
| 1–3               | 268 (66.50) | 67             | 201               | 1035.52      | 6.47        |
| 4–7               | 135 (33.50) | 42             | 93                | 552.22       | 7.60        |

### Baseline Clinical, Laboratory and ART information of children on ART

Regarding opportunistic infections at baseline, (53.85%) of HIV-infected children were experienced opportunistic infections. Of which, (19.8%) had recurrent upper respiratory tract infections followed by herpes zoster (14.7%), tuberculosis (14.7%), and bacterial pneumonia (13.8%). More than two-thirds (84.37%) of HIV-infected children took cotrimoxazole prophylaxis during ART initiation. Related to the initial ART regimen started for the participants, 37.46% of children initiated with a combination of AZT-3TC-NVP. Of the total HIV-infected children, about 45.66% of children were stunted, and 42.18% of participants were underweight (Table 3).

### Follow up laboratory and ART information

The majority (88.09%) of children had a good ART adherence during their follow-up. Two-thirds (66.75%) of HIV-infected children have changed their original ART regimen. The major (52.79%) reason for changing the regimen was the availability of new drugs (Table 4).

### Incidence of anemia during follow up period

A total of 403 HIV-infected children were followed for the overall follow-up period of 1587 person-years of observation with a minimum of one month and a maximum of 123 months. From 403 total study participants, 226 (56.08%) were on ART at the end of the study period, 14 (3.47%) were lost to follow up, 47 (11.66%) were transferred out to other health facilities, 7 (1.74%) have died, and the rest 109 (27.05%) were developed anemia.

The overall incidence density rate (IDR) during the cohort was 6.87 (95% CI = 5.60, 8.16) per 100 person-years of observation and the cumulative proportion was 27.05% (95% CI = 22.91, 31.61). The cumulative probability of anemia free at 6, 12, 24, 36 and 123 months of ART initiation was 88%, 84%, 80%, 76%, and 58%, respectively. The highest anemia incidence density rate among children on ART was 26 (95% CI = 19.63, 34.56) per 100 person-years of observation during the first 6 month of follow up and decreased to 6 (95% CI = 3.27, 11.32), 5 (95% CI = 3.08, 8.48), 4.7 (95% CI = 2.67, 8.28) and 3.3 (95% CI = 2.25, 5.01) per 100 person-years of observation in 12-month, 24-month, 36-month and > 36 month, respectively. Anemia free probability by the end of the follow up was 58% (95% CI = 51.30, 63.36) (Fig. 2).

### Log-rank test result comparison on different categorical variables

A Log-rank test was performed to test the equality of survival curves of different categorical explanatory variables. The test statistics showed a significant difference in survival function in different categorical explanatory variables.

In this study, a child aged 0.25 to 5 years had lower survival status than those greater than five years of age. The overall survival of those with age 0.25 to ≤ 5 years and > 5 years are found to be 55% and 61%, respectively (Fig. 3).

In addition, children with WHO clinical stages III & IV had lower survival times as compared to children with WHO clinical stages I & II. The median survival time of anemia-free children with stage III & IV was 117 months. The overall survival of children with WHO clinical stage III & IV and WHO clinical stage I & II were 43% and 69%, respectively (Fig. 4).
Similarly, children with underweight had lower survival status than children with not underweight. The median survival time of anemia-free for underweight children was 117 months, and the overall survival of underweight children and not underweight children was 47% and 70%, respectively (Fig. 5).

Testing the model goodness of fitness
The goodness of fit test for cox- proportional hazard regression model was done by cox -Snell residual test in which the hazard function curve follows the 45-degree line closely, as we can confirm from the graph below (Fig. 6).

Table 2  Anemia incidence density rate stratified by baseline socio-demographic characteristics of caregiver and parents information at public health facilities of Bahir Dar City, Northwest Ethiopia from 2010 to 2020

| Variable                        | N = 403 (%) | Anemia N = 109 | Censored N = 294 | Person-Years | IDR/100 PYO |
|--------------------------------|-------------|----------------|------------------|--------------|-------------|
| Age of caregiver               |             |                |                  |              |             |
| 15–30                          | 158 (39.21) | 47             | 111              | 572.44       | 8.21        |
| 31–45                          | 222 (55.09) | 55             | 167              | 927.90       | 5.93        |
| 46–65                          | 23 (5.7)    | 7              | 16               | 87.41        | 8.00        |
| Parental live status           |             |                |                  |              |             |
| Both a live                    | 250 (62.03) | 67             | 183              | 1014.50      | 6.60        |
| Only mother a live             | 76 (18.86)  | 20             | 56               | 297.47       | 6.72        |
| Only father a live             | 46 (11.41)  | 16             | 40               | 157.62       | 10.15       |
| Both dead                      | 21 (5.21)   | 4              | 17               | 93.37        | 4.28        |
| Unknown                        | 10 (2.48)   | 2              | 8                | 24.77        | 8.07        |
| Relation of caregiver          |             |                |                  |              |             |
| Parent                         | 363 (90.07) | 102            | 261              | 1417.13      | 7.19        |
| Guardian                       | 40 (9.93)   | 7              | 33               | 170.62       | 4.10        |
| Educational status of the caregiver |         |                |                  |              |             |
| Unable to read and write       | 92 (22.83)  | 22             | 70               | 345.31       | 6.37        |
| Primary education              | 117 (29.03) | 34             | 83               | 478.56       | 7.10        |
| Secondary education            | 78 (19.35)  | 27             | 51               | 300.24       | 8.99        |
| College/University level       | 116 (28.78) | 26             | 90               | 463.64       | 5.60        |
| HIV status                     |             |                |                  |              |             |
| Both parents positive          | 180 (44.67) | 46             | 134              | 753.82       | 6.10        |
| Mother positive                | 128 (31.76) | 37             | 91               | 519.57       | 7.12        |
| Father positive                | 30 (7.44)   | 13             | 17               | 78.84        | 16.48       |
| Father negative                | 4 (0.99)    | 0              | 4                | 27.49        | 0          |
| Caregiver positive             | 2 (0.50)    | 0              | 2                | 8.38         | 0          |
| Caregiver negative             | 15 (3.72)   | 4              | 11               | 53.26        | 7.51        |
| Unknown                        | 44 (10.92)  | 9              | 35               | 146.37       | 6.14        |
| Marital status of the caregiver |         |                |                  |              |             |
| Single                         | 31 (7.69)   | 7              | 24               | 110.33       | 6.34        |
| Married                        | 250 (62.03) | 68             | 182              | 992.19       | 6.85        |
| Divorced                       | 24 (5.96)   | 12             | 12               | 98.19        | 12.22       |
| Widowed                        | 98 (24.32)  | 22             | 76               | 387.03       | 5.68        |
| Occupational status of the caregiver |     |                |                  |              |             |
| Government employee            | 111 (27.54) | 25             | 86               | 445.77       | 5.60        |
| Farmer                         | 35 (8.68)   | 9              | 26               | 127.98       | 7.03        |
| Merchant                       | 86 (21.34)  | 27             | 59               | 307.23       | 8.78        |
| House wife                     | 77 (19.11)  | 20             | 57               | 305.92       | 6.53        |
| Daily worker                   | 59 (14.64)  | 20             | 39               | 243.10       | 8.22        |
| Self-employee                  | 35 (8.68)   | 8              | 27               | 157.72       | 5.07        |

IDR Incidence density rate, PYO Person-years of observation
Table 3  Anemia incidence density rate stratified by baseline Clinical, Laboratory, and ART information of children at public health facilities of Bahir Dar City, Northwest Ethiopia from 2010 to 2020

| Variable                              | N = 403 (%) | Anemia N = 109 | Censored N = 294 | Person-Years | IDR/100 PYO |
|---------------------------------------|-------------|----------------|------------------|--------------|-------------|
| WHO clinical stage                    |             |                |                  |              |             |
| Stage I / II                          | 279 (69.23) | 63             | 216              | 1114.03      | 5.65        |
| Stage III / IV                        | 124 (30.77) | 46             | 78               | 473.71       | 9.71        |
| CD4 count                             |             |                |                  |              |             |
| > 350 cells/µl                        | 242 (60.05) | 63             | 179              | 916.58       | 6.87        |
| 350 – 200 cells/µl                    | 95 (23.57)  | 26             | 69               | 409.28       | 6.35        |
| ≤ 200 cells/µl                        | 66 (16.38)  | 20             | 46               | 261.88       | 7.64        |
| OI at baseline                        |             |                |                  |              |             |
| Yes                                   | 217 (53.85) | 66             | 151              | 903.76       | 7.30        |
| No                                    | 186 (46.15) | 43             | 143              | 683.98       | 6.28        |
| Cotrimoxazole Prophylaxis             |             |                |                  |              |             |
| Yes                                   | 340 (84.37) | 92             | 248              | 1405.16      | 6.54        |
| No                                    | 63 (15.63)  | 17             | 46               | 182.59       | 9.31        |
| History of past TB                    |             |                |                  |              |             |
| Yes                                   | 15 (3.72)   | 1              | 14               | 57.322       | 1.74        |
| No                                    | 388 (96.28) | 108            | 280              | 1530.42      | 7.05        |
| Isoniazid prophylaxis                 |             |                |                  |              |             |
| Yes                                   | 97 (24.07)  | 22             | 75               | 312.06       | 7.04        |
| No                                    | 306 (75.93) | 87             | 219              | 1275.69      | 6.81        |
| ART regimen started                   |             |                |                  |              |             |
| AZT-3TC-NVP                           | 151 (37.46) | 53             | 98               | 603.04       | 10.62       |
| d4T-3TC-NVP                           | 60 (14.88)  | 21             | 39               | 260.56       | 8.05        |
| d4T-3TC-EFV                           | 14 (3.47)   | 1              | 13               | 88.65        | 1.12        |
| AZT-3TC-EFV                           | 95 (23.57)  | 22             | 73               | 393.52       | 5.59        |
| TDF-3TC-EFV                           | 26 (6.45)   | 2              | 24               | 104.82       | 1.90        |
| ABC-3TC-LPV/r                        | 20 (4.96)   | 6              | 14               | 35.80        | 16.75       |
| ABC-3TC-EFV                           | 11 (2.73)   | 1              | 10               | 44.70        | 2.23        |
| ABC-3TC-NVP                           | 11 (2.73)   | 3              | 8                | 40.08        | 7.48        |
| TDF-3TC-DTG                           | 1 (0.25)    | 0              | 1                | 0.89         | 0           |
| ABC-3TC-DTG                           | 8 (1.99)    | 0              | 8                | 8.71         | 0           |
| ABC-3TC-EFV                           | 1 (0.25)    | 0              | 1                | 7.66         | 0           |
| AZT-3TC-LPV/r                        | 1 (0.25)    | 0              | 1                | 0.33         | 0           |
| ABC-3TC-NVP                           | 1 (0.25)    | 0              | 1                | 2.74         | 0           |
| TDF-3TC-NVP                           | 3 (0.74)    | 0              | 3                | 18.14        | 0           |
| Time of ART initiation                |             |                |                  |              |             |
| Early initiation                      | 72 (17.87)  | 17             | 55               | 188.87       | 9.00        |
| Late initiation                       | 331 (82.13) | 92             | 239              | 1398.87      | 6.57        |
| Height/length for age (< 15 years)    |             |                |                  |              |             |
| Normal                                | 219 (54.34) | 52             | 167              | 910.93       | 5.71        |
| Stunted                               | 184 (45.66) | 57             | 127              | 676.81       | 8.42        |
| Height/length for weight (< 5 years)  |             |                |                  |              |             |
| Normal                                | 93 (77.50)  | 30             | 63               | 363.19       | 8.25        |
| Wasted                                | 27 (22.50)  | 9              | 18               | 97.46        | 9.23        |
| Weight for age (< 10 years) or BMI for age (> 5 years) |  | | | | |
| Not under weight                      | 233 (57.82) | 52             | 181              | 968.98       | 5.36        |
| Under weight                          | 170 (42.18) | 57             | 113              | 618.76       | 9.21        |

*IDR* incidence density rate, *PYO* Person years of observation
Table 4  Anemia incidence stratified by follow up laboratory and ART information of children on ART at public health facilities of Bahir Dar City, Northwest Ethiopia, from 2010 to 2020

| Variable                          | N = 403 (%) | Anemia N = 109 | Censored N = 294 | Person- Years | IDR/100 PYO |
|-----------------------------------|-------------|----------------|------------------|---------------|-------------|
| Viral load                        |             |                |                  |               |             |
| ≤ 1000 copies/ml                 | 333 (82.63) | 88             | 245              | 1331.15       | 6.61        |
| > 1000 copies/ml                 | 70 (17.37)  | 21             | 49               | 256.59        | 8.18        |
| Level of ART adherence           |             |                |                  |               |             |
| Good                             | 355 (88.09) | 88             | 267              | 1413.24       | 6.22        |
| Fair/Poor                        | 48 (11.91)  | 21             | 27               | 174.50        | 12.03       |
| Side effect                      |             |                |                  |               |             |
| Yes                              | 51 (12.66)  | 29             | 22               | 151.51        | 19.14       |
| No                               | 352 (87.34) | 80             | 272              | 1436.23       | 5.57        |
| Regimen change                   |             |                |                  |               |             |
| Yes                              | 269 (66.75) | 85             | 184              | 1158.64       | 7.33        |
| No                               | 134 (33.25) | 24             | 110              | 429.10        | 5.59        |
| Reason for regimen change (n = 269) |         |                |                  |               |             |
| Toxicity/side effect             | 67 (24.91)  | 32             | 55               | 250.46        | 12.77       |
| New drug available               | 142 (52.79) | 36             | 106              | 611.13        | 5.89        |
| Drug stock out                   | 30 (11.15)  | 10             | 20               | 149.24        | 6.70        |
| New tuberculosis                 | 3 (1.12)    | 0              | 3                | 15.09         | 0           |
| Treatment failure                | 27 (8.55)   | 7              | 20               | 108.39        | 6.45        |
| Others                           | 4 (1.49)    | 0              | 4                | 24.3          | 0           |
| Follow up time in month          |             |                |                  |               |             |
| 1–6                              | 64 (15.88)  | 48             | 16               | 184.25        | 26.05       |
| 6–12                             | 24 (5.96)   | 10             | 14               | 164.14        | 6.09        |
| 12–24                            | 42 (10.42)  | 15             | 27               | 293.16        | 5.11        |
| 24–36                            | 42 (10.42)  | 12             | 30               | 255.14        | 4.70        |
| > 36                             | 231 (57.32) | 24             | 207              | 714.15        | 3.36        |

Others include patient preference and not recorded the reason for regimen change, IDR Incidence density rate, PYO Person years of observation

Fig. 2  The overall Kaplan Meier survival estimate of HIV-infected children on ART at public health facilities of Bahir Dar City, Northwest Ethiopia, from 2010 to 2020.
The temporal relationship between the baseline variables and the risk of anemia on HIV-infected children on ART was analyzed using the Cox proportional hazard regression model. In bivariable analysis, the Cox proportional hazard regression model showed the age of the child, the relation of caregiver to a child, marital status of the caregiver, WHO clinical stage, height for age, weight for age / BMI for age, history of past TB, ART adherence and ART regimen were identified as predictors of anemia. In the multivariable analysis, only child’s age, WHO clinical stage, weight for age / BMI for age, ART adherence, and ART regimen were predictors of anemia.

This study finding showed that the hazard of anemia in children whose age was between 0.25–5 years was 1.83 (95% CI = 1.22, 2.77) times higher than children whose age was > 5 years. Similarly, a hazard of anemia in children with WHO clinical stage III and IV had increased 1.8 (95% CI = 1.22, 2.67) times compared to children with WHO clinical stage I and II. In addition to this, being underweight increased the
hazard of anemia by 1.50 (95% CI = 1.01, 2.26) times compared to children who are not underweight. Children with fair/poor ART adherence have increased the hazard of anemia by 1.75 (95% CI = 1.08, 2.85) times compared with children who had good ART adherence levels. Furthermore, the hazard of anemia in children who started AZT-based ART regimen was 1.72 (95% CI = 1.12, 2.64) times higher than those who started non-AZT-based ART regimen (Table 5).

Discussion
This study’s overall incidence density rate was higher than the studies conducted in Asia (Cambodia, India, Indonesia, Malaysia, Vietnam, and Thailand), reported 5.4 per 100 person-years of observation [11]. And West Africa (Benin, Burkina Faso, Cote d’Ivoire, Gambia, Ghana, Mali, and Senegal) revealed 2.47 per 100 children-years observation in those on Zidovudine containing regimen versus 4.25 in those non-zidovudine based regimens [8].
This difference might be due to differences in ART drug regimen and multi-centeredness. Because both previous studies were done with multi-center at country level, but this study was done the multicentered at the health facility level. Moreover, the previous research reported only severe anemia incidence, but the current study reported the incidence of all types of anemia. In the study conducted in West Africa, the follow-up time included only the duration of first-line antiretroviral therapy, but this study included the follow-up time after first-line ART was changed to the second-line/third-line ART drug. On the other side, the overall incidence density rate of the current study was lower than the study conducted in Gondar, Ethiopia, 10.5 per 100 person-years of observation [12].

The current study showed that the hazard of anemia in children whose age between 0.25—5 years was higher than children whose age was greater than five years. This study is supported by the study conducted in West Africa, India, and Uganda [5, 8, 23]. Due to that, children in this age group had an increased micronutrient requirement for growth and a higher frequency of gastrointestinal infections. Since the disease progression is fast, they are more at risk for malnutrition and opportunistic infections. In addition, the most common cause of anemia in under-five children is low consumption and absorption of iron-rich foods (i.e., meat and meat products). These conditions most often lead to iron deficiency anemia, accounting for approximately half of all anemia cases globally [9, 23, 28].

Similarly, the hazard of anemia in children with an advanced WHO clinical stage of disease during ART had increased 1.8 times as compared to their counterparts. This study is supported by the study conducted in India and Uganda [5, 23]. It can be explained that being in the advanced stage of the disease causes compromised immunity, which leads to increased viral multiplication and higher loads of opportunistic infections.

This causes anemia through increased cytokine-mediated myelosuppression and a higher burden of comorbidities [5]. This study showed that being underweight at the baseline increased the hazard of anemia by 1.50 times compared to children who are not underweight. It is in line with the study done in Asia, West Africa, and a previous study in Ethiopia [8, 11, 12] because children with underweight will have intestinal mal-absorption and micronutrient deficiency, like iron, folic acid, vitamin A, and vitamin B12 [29, 30] which leads to anemia.
In this study, children having fair/poor ART adherence during follow-up time increased the hazard of anemia by 1.75 times compared to children who had good ART adherence levels. This statistically associated result is supported by the study conducted in Ethiopia [31]. The possible explanation for this might be those children who had fair/poor ART adherence are at a greater risk of high viral load duplication, suppression of immunity, fast progression of the disease, development of opportunistic infections, drug resistance. And further clinical deterioration may occur, resulting in anemia via cytokine-mediated myelosuppression [32, 33]. Furthermore, the current study showed that the hazard of anemia in children who started AZT-based ART regimen during initiation was 1.72 times higher than those who started non-AZT-based ART regimen. It is supported by studies conducted in India, Asia, and Ethiopia [11, 12, 21]. Due to that, treatment with Zidovudine results in suppressions of bone marrow and other hematopoietic activities, which leads to low production of red blood cells and other types of blood cells in the bone marrow. Another mechanism of Zidovudine-induced anemia is mainly attributable to inhibition of proliferation of blood cell progenitor cells in a time and dose-dependent fashion [34–36].

Limitation of the study
Since the data were collected from a secondary source of medical records, other important predictors of anemia, like income, food diversification, intestinal parasite infections, maternal serum hemoglobin level, and serum ferritin level were not assessed. In addition, there might be selection bias because there were incomplete charts that were excluded from the analysis.

Conclusion
The overall incidence rate of anemia was high compared to other country reports. Age, clinical, and ART-related variables provoked the incidence of anemia. Therefore, a need to emphasize the younger age group, prevent and manage opportunistic infections of WHO clinical stage III and IV, and select and monitor appropriate ART regimens.

Recommendation
To policymakers
It is strongly advised to strengthen a good ART adherence level. Optimum adherence is highly essential for sustainable success to highly active antiretroviral treatment because ART drug has an effect on preventing anemia among clients living with HIV/AIDS taking ART drugs.

To clinicians
Give special focus on identified predictors of anemia incidence in this study. Especially children who started ART with Zidovudine-based ART regimen, 0.25—≤5 years, WHO clinical stage III & IV, fair/Poor ART adherence level, and for those children being underweight to reduce the incidence rate of anemia among children on ART.

To future researchers
A prospective study design is recommended to identify additional predictors of anemia among children on ART like food diversification, maternal serum hemoglobin level, and serum ferritin level, which are found by the primary data source.

Abbreviations
AHR: Adjusted Hazard Ratio; AIDS: Acquired Immunodeficiency Syndrome; ART: Antiretroviral Therapy; AZT: Zidovudine; BMI: Body Mass Index; CD4: Cluster of Differentiation 4; CI: Confidence Interval; CPT: Cotrimoxazole Prophylactic Therapy; EDHS: Ethiopian Demographic Health Survey; HAART: Highly Active Antiretroviral Therapy; HIV: Human Immunodeficiency Virus; HGB: Hemoglobin; IRB: Institutional Review Board; OI: Opportunistic Infection; PCV: Packed Cell Volume; RBC: Red Blood Cell; TB: Tuberculosis; WHO: World Health Organization.

Acknowledgements
The authors’ deepest gratitude goes to Bahir Dar University, College of Medicine and Health Sciences, to support this study. The authors also acknowledged ART clinic staff, supervisor, data collectors, and card room workers for their cooperation during data collection.

Authors’ contributions
GK, AE, and YA worked on developing the research idea, designing the study, being involved in proposal writing, training and supervising the data collectors, analyzing and interpreting the results, and preparing the manuscript. MT, BB, NM, AT, ES, MA, TM, DG, AK, and DK played their role in critically revising the proposal, participating in its design, analyzing and interpreting the results, and writing the manuscript. All authors were involved in reading and approving the final manuscript.

Funding
Financial support was obtained from Bahir Dar University. The funding institution has no role in the preparation of the manuscript as well as the decision to publish.

Availability of data and materials
The datasets generated during the current study are not publicly available due to confidentiality issues since the study was conducted among HIV-infected children. But data will be available upon reasonable request from the corresponding author.

Declarations
Ethics approval and consent to participate
Ethical clearance was obtained from Bahir Dar University, College of Medicine and Health Sciences, Ethical Clearance Review Committee with protocol number 068/2021 and Institutional Review Board decision number 003, and consent waiver was obtained from the Ethics committee, namely (Bahir Dar University, College of Medicine and Health Sciences Institutional Review Board). Then, the data were collected after getting a support letter from the administrative bodies of each health institution. This study did not expose HIV-infected children to unnecessary risk due to reviewing their medical records. Confidentiality was kept at all levels of the study, and the data was used only
University of Gondar Hospital and Gondar Poly Clinic, Northwest Ethiopia: a cross-sectional institutional-based study. BMC Public Health. 2014;14(1):1–6.

34. Ejelogo EU, Oguche S, Ebonyi AO, Okpe SE, Yiltok ES, Ige O, et al. Zidovudine-induced anemia in human immunodeficiency virus-infected children on highly active antiretroviral therapy in Jos, Nigeria. 2014.

35. Dash KR, Meher LK, Hui P, Behera S, Nayak S. High incidence of Zidovudine induced anemia in HIV infected patients in Southern Odisha. Indian J Hematol Blood Transfus. 2015;31(2):247–50.

36. Chatterjee A, Bosch RJ, Kupka R, Hunter DJ, Msamanga GI, Fawzi WW. Predictors and consequences of anemia among antiretroviral-naive HIV-infected and HIV-uninfected children in Tanzania. Public Health Nutr. 2010;13(2):289–96.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.